Immune Checkpoint Therapy Clinical Trials

7 recruiting

Immune Checkpoint Therapy Trials at a Glance

7 actively recruiting trials for immune checkpoint therapy are listed on ClinicalTrialsFinder across 5 cities in 2 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Dublin, and Houston. Lead sponsors running immune checkpoint therapy studies include Sixth Affiliated Hospital, Sun Yat-sen University, M.D. Anderson Cancer Center, and Oxford Biodynamics Inc..

Browse immune checkpoint therapy trials by phase

About Immune Checkpoint Therapy Clinical Trials

Looking for clinical trials for Immune Checkpoint Therapy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Checkpoint Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Checkpoint Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Immune Checkpoint Therapy
M.D. Anderson Cancer Center980 enrolled1 locationNCT06337097
Recruiting
Phase 2

Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial

RadiotherapyNeoadjuvant TherapiesImmune Checkpoint Therapy
Sixth Affiliated Hospital, Sun Yat-sen University52 enrolled1 locationNCT07230639
Recruiting
Phase 2

Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial

Colon CancerRadiation TherapyNeoadjuvant Therapies+1 more
Sixth Affiliated Hospital, Sun Yat-sen University38 enrolled1 locationNCT07279077
Recruiting
Phase 2Phase 3

Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)

RadiotherapyMetastatic Colorectal Cancer (CRC)Immune Checkpoint Therapy
Sixth Affiliated Hospital, Sun Yat-sen University286 enrolled1 locationNCT06958419
Recruiting
Phase 2Phase 3

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Rectal CancerRadiotherapyNeoadjuvant Therapies+1 more
Sixth Affiliated Hospital, Sun Yat-sen University430 enrolled1 locationNCT06958432
Recruiting
Phase 2

Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

Rectal CancerRadiotherapyNeoadjuvant Therapies+1 more
Sixth Affiliated Hospital, Sun Yat-sen University80 enrolled1 locationNCT06923345
Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc.2,000 enrolled3 locationsNCT06635954